Patrick Chaltin News Today

The new capital is provided by KU Leuven Research & Development (LRD) and the European Investment Fund (EIF), whose contribution is supported under the European Commission’s InvestEU initiative, as well as by the Gemma Frisius Fund (GFF). It will be used to transform groundbreaking biomedical discoveries from both biotech companies and especially academic research groups at KU Leuven and other universities, into new medicines that improve people’s lives worldwide.

KU Leuven’s Rega Institute for Medical Research and the Centre for Drug Design and Discovery (CD3) today announced that they recently entered into a collaboration and license agreement with Gilead Sciences, Inc. to develop candidate antiviral compounds for the treatment of respiratory syncytial virus (RSV) infection. RSV is the single most common cause of respiratory hospitalization in children under the age of five, and a significant cause of mortality in this population.

 Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has selected ALG-097558, a broad spectrum coronavirus protease inhibitor, as its drug candidate to move forward into development.

Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), along with CD3 and LICR at KU Leuven, announced today that they have entered into an exclusive global license and research agreement to develop and commercialize first-in-class TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders.

/PRNewswire/ -- Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), along with CD3 and LICR at KU Leuven,...

/PRNewswire/ -- Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), along with CD3 and LICR at KU Leuven,...

GuruFocus Article or News written by PRNewswire and the topic is about:

Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain - read this article along with other careers information, tips and advice on BioSpace

Researchers have developed a potent inhibitor of the dengue virus, which causes roughly 100 million cases of symptomatic cases of dengue fever annually.

Researchers at the KU Leuven Rega Institute and CD3 have developed an ultrapotent inhibitor of the dengue virus, which causes the tropical disease known as dengue. The teams collaborated closely with Janssen Pharmaceutica, N.V. The antiviral molecule is exceptionally effective against all known dengue variants and could be used for therapeutic and prevention purposes. The teams have published their findings in Nature.